Trump Administration Invests in Innovative PTSD Treatment
In a significant move following Veterans Day, the Trump administration announced a substantial investment aimed at exploring an unconventional approach to treating post-traumatic stress disorder (PTSD).
Robert F. Kennedy Jr., Secretary of the Department of Health and Human Services (HHS), disclosed that nearly $5 million will be directed towards research focused on ibogaine, a potent psychedelic compound showing promise for PTSD and other mental health issues.
“Veterans upheld their commitment to our nation; it is our duty to uphold ours,” stated Kennedy. He emphasized the urgent need for thorough scientific investigation into veterans’ claims that ibogaine has transformed their lives. “We will approach the evidence with diligence, address the risks, and prioritize affordability throughout this process.”
@SecKennedy makes MAJOR ANNOUNCEMENT on investments to advance research into ibogaine as a potential treatment for PTSD! “@HHSGov is committing up to $4.9 million through @ARPA_H to advance ibogaine treatments for PTSD. These awards will support the scientific, regulatory, and manufacturing work necessary to prepare for future U.S. clinical trials.”
— HHS Rapid Response (@HHSResponse) November 12, 2026
The funding, sourced from HHS’s Advanced Research Projects Agency for Health (ARPA-H), aims to facilitate the groundwork necessary for upcoming clinical trials of ibogaine within the United States.
Ibogaine, a naturally occurring psychedelic derived from a West African shrub, has gained traction in recent years as a potential remedy for PTSD, depression, and substance dependency. Several veterans have even sought this treatment abroad.
Additionally, Kennedy announced a further allocation of $20 million to investigate other rapid-acting mental health therapies, including ketamine and psilocybin.
This announcement follows an executive order issued by President Trump in April, which aims to expedite research into emerging mental health treatments. The HHS is collaborating with the Veterans Administration (VA) to ensure these therapies become available to veterans as soon as they receive regulatory approval from the FDA.
Doug Collins, Secretary of the VA, expressed support for this initiative, stating, “Veterans deserve access to effective treatment options and clear information regarding the benefits and potential risks of these therapies.” He added, “We look forward to partnering with HHS to explore the potential of ibogaine and to prepare our healthcare providers for delivering new treatments upon FDA approval.”
Editor’s Note: Here at RedState, we are committed to fighting against radical ideologies and providing the conservative reporting our readers expect.
Support our mission to uncover the truth about the Trump administration and its achievements. Become a RedState VIP member and use promo code FIGHT for a 60% discount on your membership.
Discussion about this post